Literature DB >> 29558252

Ibrutinib for the Management of Schnitzler Syndrome: A Novel Therapy for a Rare Condition.

Prachi Jani1, Megan B Vissing1, Salman Ahmed1, Jason C Sluzevich1, Sonikpreet Aulakh1, Victoria Alegria1, Meghna Ailawadhi1, Asher Chanan-Khan1, Sikander Ailawadhi1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29558252     DOI: 10.1200/JOP.18.00050

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  1 in total

1.  Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome.

Authors:  Yuehua Huang; Yanying Wang; Fan Yu; Xuehan Mao; Bianhong Wang; Jingxian Li; Lihong Li
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.